Multi-omics biomarker panels can predict neurodegenerative disease progression 5-10 years before symptom onset—and blood tests are approaching CSF accuracy

The shift from single biomarkers to multi-omics panels is transforming how we predict neurodegenerative disease progression. Blood-based tests are now approaching the accuracy of CSF analysis, making early prediction scalable.

Full analysis below ↓